ascopubs.org6d
Mental health monitoring in clinical trials for FDA-approved genitourinary cancer treatments: A decade review.
Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.
ascopubs.org6d
Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors. PSMA-positive tumor vessels around renal cell carcinoma ...
ascopubs.org6d
Evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma.
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
ascopubs.org1d
Management of relapsed primary retroperitoneal (RP) germ-cell tumor (GCT) after front-line chemotherapy.
Therapeutic approaches and outcomes in patients aged 50+ with germ cell tumours. Survival outcomes by salvage chemotherapy received.
ascopubs.org6d
Concordance between clinical and pathologic staging of T2a–b and T3a renal cell carcinoma.
Renal cell carcinoma in kidney transplant recipients receiving immunosuppression: A 55-year retrospective single-center study.
ascopubs.org6d
Predicting long term outcomes following radical prostatectomy using a validated pathology-based multimodal artificial intelligence biomarker.
Real-world U.S. county-level analysis of erectile dysfunction diagnosis following radiation therapy for localized prostate cancer: The impact of rectal spacer utilization. This is an ASCO Meeting ...
ascopubs.org1d
Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate immune niches in high- versus low-grade tumors.
Developing a deep learning algorithm for automated p53 immunohistochemistry digital image analysis in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
ascopubs.org6d
Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation.
Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy. Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase ...
ascopubs.org6d
Early findings from a national quality improvement (QI) program to address disparities in bladder cancer (BLCA) care.
Mental health monitoring in clinical trials for FDA-approved genitourinary cancer treatments: A decade review. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
ascopubs.org6d
Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.
Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic ...
ascopubs.org6d
Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment.
Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
ascopubs.org6d
HIF2α gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid differentiation.
Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.